Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Rhea-AI Summary

Sunshine Biopharma (NASDAQ: SBFM) announced a collaboration with a leading lipid nanoparticle (LNP) company to further develop its mRNA-based anticancer macromolecule, K1.1. The partnership aims to create two LNP formulations, K1.1a and K1.1b, to conduct in vivo studies on human cancer models. Previously, K1.1 has shown effectiveness against various cancer cell types without harming normal human cells. The success of these studies could expedite human clinical trials. Sunshine Biopharma also continues its work on other cancer therapies and a COVID-19 treatment.

Positive

• Collaboration with a leading LNP company enhances K1.1 macromolecule development.
• K1.1 mRNA previously demonstrated effectiveness against multiple cancer types.
• Potential rapid advancement to human clinical trials if in vivo studies succeed.

Negative

• None.

MONTREAL, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreement with one of North America’s leading lipid nanoparticle (“LNP”) companies. The purpose of the collaboration is to advance the development of Sunshine Biopharma’s mRNA-based anticancer macromolecule, K1.1.

The Company’s collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma’s in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma had previously shown that its K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Parallel studies using normal human cells (HMEC) showed that K1.1 mRNA had little or no cytotoxic effects.

The partner generated K1.1a::LNP and K1.1b::LNP will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials. The LNP formulated K1.1 mRNA can be readily adapted for delivery into patients using the recently gained knowledge from the mRNA vaccine technology.

“We are delighted to be working with our new partner and their fully integrated team of experts in LNP technology,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

About Sunshine Biopharma Inc.

Sunshine Biopharma recently acquired Nora Pharma Inc. and as a result the Company now has 36 employees and 50 generic prescription drugs on the market in Canada. In parallel, Sunshine Biopharma is continuing its drug development R&D program. In addition to the K1.1 anticancer mRNA project, the Company is working on the development Adva-27a, a small molecule having the unique ability to destroy multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells, and uterine sarcoma cells. Clinical trials for pancreatic cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a COVID-19 treatment in collaboration with the University of Arizona. The project, currently in advanced stages of preclinical studies, is focused on the development of an inhibitors for SARS-CoV-2 PLpro protease. PLpro is unique to the SARS group of Coronaviruses and is responsible for suppressing the human immune system making this group of viruses more deadly.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the “Company”) that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company’s drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.

For Additional Information:

Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com

Sunshine Biopharma Media Contact:
Christine Petraglia
TraDigital IR
Direct Line: 917-633-8980
investors@sunshinebiopharma.com

FAQ

What is the recent collaboration involving Sunshine Biopharma (SBFM)?

Sunshine Biopharma has announced a collaboration with a lipid nanoparticle company to advance the development of its mRNA-based anticancer macromolecule, K1.1.

What are the key goals of Sunshine Biopharma's K1.1 project?

The K1.1 project aims to create LNP formulations for in vivo studies, with potential rapid transition to human trials upon success.

What types of cancer has K1.1 shown effectiveness against?

K1.1 has shown the ability to destroy breast cancer, ovarian adenocarcinoma, and pancreatic cancer cells.

What is the significance of LNP formulations K1.1a and K1.1b?

K1.1a and K1.1b are designed for in vivo studies, which could significantly advance Sunshine Biopharma's oncology treatments.